Key result
The p.(Ser96Ala) polymorphism in the histidine-rich calcium binding protein was not associated with life-threatening arrhythmias or heart failure-related events in patients with cardiomyopathy.
Why the study?
The HRC p.(Ser96Ala) polymorphism was previously associated with life-threatening arrhythmias in idiopathic DCM, but whether it modifies major cardiac manifestations across other cardiomyopathy cohorts remained unknown.
Does the HRC p.(Ser96Ala) polymorphism increase the risk of life-threatening arrhythmias or heart failure-related events in patients with cardiomyopathies?
Cohort
Does the HRC p.(Ser96Ala) polymorphism increase the risk of life-threatening arrhythmias or heart failure-related events in patients with cardiomyopathies?
The HRC p.(Ser96Ala) polymorphism does not act as a secondary hit or modifier for life-threatening arrhythmias or heart failure events in patients with arrhythmogenic or dilated cardiomyopathy, refuting previous findings.
No association with events in cardiomyopathy; challenges prior modifier reports but hypothesis-generating pending larger prospective studies.
Inherited forms of arrhythmogenic and dilated cardiomyopathy (ACM and DCM) are characterized by variable disease expression and age-related penetrance. Calcium (Ca2+) is crucially important for proper cardiac function, and dysregulation of Ca2+ homeostasis seems to underly cardiomyopathy etiology. A polymorphism, c.286T>G p.(Ser96Ala), in the gene encoding the histidine-rich Ca2+ binding (HRC) protein, relevant for sarcoplasmic reticulum Ca2+ cycling, has previously been associated with a marked increased risk of life-threatening arrhythmias among idiopathic DCM patients. Following this finding, we investigated whether p.(Ser96Ala) affects major cardiac disease manifestations in carriers of the phospholamban (PLN) c.40_42delAGA; p.(Arg14del) pathogenic variant (cohort 1); patients diagnosed with, or predisposed to, ACM (cohort 2); and DCM patients (cohort 3). We found that the allele frequency of the p.(Ser96Ala) polymorphism was similar across the general European–American population (control cohort, 40.3–42.2%) and the different cardiomyopathy cohorts (cohorts 1–3, 40.9–43.9%). Furthermore, the p.(Ser96Ala) polymorphism was not associated with life-threatening arrhythmias or heart failure-related events across various patient cohorts. We therefore conclude that there is a lack of evidence supporting the important role of the HRC p.(Ser96Ala) polymorphism as a modifier in cardiomyopathy, refuting previous findings. Further research is required to identify bona fide genomic predictors for the stratification of cardiomyopathy patients and their risk for life-threatening outcomes.
No takes yet. Share an insight, caveat, or question.
Voorn et al. (2023) conducted a cohort in Arrhythmogenic and dilated cardiomyopathy (ACM and DCM). p.(Ser96Ala) polymorphism in the histidine-rich Ca2+ binding (HRC) protein vs. General European-American population / non-carriers was evaluated on Life-threatening arrhythmias or heart failure-related events. The p.(Ser96Ala) polymorphism in the histidine-rich calcium binding protein was not associated with life-threatening arrhythmias or heart failure-related events in patients with cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: